News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

StemCells Inc. (STEM) Interim Results Show Improvement In Visual Function And Slowing Of Disease Progression In Phase 1/2 Dry AMD Trial


6/19/2014 8:40:53 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEWARK, Calif., June 19, 2014 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) reported positive interim results from its Phase I/II clinical trial of the Company's proprietary HuCNS-SCĀ® human neural stem cell platform in dry age-related macular degeneration (AMD) yesterday evening at the 12th annual meeting of the International Society for Stem Cell Research (ISSCR) in Vancouver, Canada.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES